Summary
Chairpersons: Dr Maddalena LETTINO (ESC), Prof. Julia MASCHERBAUER (ESC), Dr Matias NORDABY (Boehringer-Ingelheim), Dr André ZIEGLER (Roche Diagnostics), Dr Isabelle RICHARD-LORDEREAU (Amgen), Industry chair of the CRT
12 May Replay - Session 1
12 May Replay - Session 2
13 May Replay - Session 1
13 May Replay - Session 2
Background and objectives of the meeting
The growing elderly population worldwide represents a major challenge for care-givers, healthcare providers and politicians.
Due to the life-long exposure to cardiovascular risk factors and the age-related comorbidities, cardiovascular diseases in elderly patients have a high prevalence and are frequently complicated, thus deserving a multifactorial approach.
Major problems to deal with are: paucity of scientific evidence from dedicated clinical trials, a narrow therapeutic window for most of the recommended therapies, frailty and cognitive deterioration, all affecting quality of care and outcome.
This meeting will appraise the burden of ageing in real life and the opportunity to revisit cardiovascular research, as well as pharmacological and interventional treatments in the elderly, with a final focus on quality of life and patient’s priorities.
Programme
| DAY 1 | 12 MAY 2021 – 14:00 – 16:45 CET |
|---|---|
| 14:00 - 14:05 | Welcome and introduction Chairpersons |
| 14:05 - 14:15 | Introductory talk: How to define and measure ageing? Dr Maddalena Lettino, ITDr Isabelle Richard-Lordereau, Amgen |
| SESSION 1 - THE BURDEN OF AGEING IN REAL LIFE | |
| 14:15 - 14:25 | Co-Morbidities and Risk Factors in the Ageing Population Prof. Frank Visseren, NL |
| 14:25 - 14:35 | Benefits of Primary Prevention/ Lifestyle in the Elderly Dr Deirdre E. O’Neill, CA |
| 14:35 - 15:15 |
Discussion |
| 15:15 - 15:45 | Break |
| SESSION 2 – TAILORED CVD MANAGEMENT IN THE ELDERLY | |
| 15:45 - 15:55 | EMA recommendations - for CVD research in the Elderly - for trials for the elderly / looking for an indication - lack of evidence Dr Kristina Dunder, NO |
| 15:55 - 16:05 | Similarities and differences in CV ageing in men and women Prof. Geneviève Derumeaux, FR |
| 16:05 - 16:45 | Discussion |
| 16:45 |
Wrap-up - End of DAY 1 – Let’s meet tomorrow for the 2 final sessions |
| DAY 2 | 13 MAY 2021 - 14:00 – 16:45 CET |
|---|---|
| 14:00 - 14:05 | Summary of Day 1 Chairpersons |
| SESSION 3 - LEARNINGS FROM TREATMENTS SPECIFICITIES IN THE ELDERLY | |
| 14:05 - 14:15 | Challenges in Antithrombotics Treatments Antiplatelets – Anticoagulants (discussion on combination) Prof. Stefan Hohnloser, DE |
| 14:15 - 14:25 | Challenges in Intervention Decision-Making for Invasive Procedures in the Elderly (PCI, TAVI, Mitraclip…) Prof. Jean-Philippe Collet, FR |
|
14:25 - 15:00 |
Discussion |
| 15:00 - 15:30 | Break |
| SESSION 4 - HOW TO ARTICULATE SOCIAL CARE AND HEALTH CARE PRIORITIES? | |
| 15:30 - 15:40 | The Patient Perspective – Interview of a Patient Video |
| 15:40 - 15:50 | Adding Years to Life or Life to Years: The Ethical dimension (choices tree for Palliative Care/ focus on CV / Quality of Life) Dr Herbert Watzke, AT |
| 15:50 - 16:35 | Discussion |
|
16:35 - 16:45 |
Wrap-up – Key messages – Next steps - Publication |
| END OF DAY 2 |
|
Our mission: To reduce the burden of cardiovascular disease.